FDAShortage list
FDA reaffirms the tirzepatide shortage is resolved
After a short reconsideration, the FDA reaffirmed that the tirzepatide shortage was over, again requiring compounders to wind down production of copies. As with semaglutide, removal from the shortage list removes the basis that permitted compounded tirzepatide, tightening the supply of versions sold outside the approved products.
Source
https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortagesThe issuing body’s own page is authoritative. PepIndex records what it says and when we recorded it; where the two disagree, the source governs.
Compounds affected
Ranked vendors for Tirzepatide
Every vendor and price for Tirzepatide →- 1
Origin Labs1 Tirzepatide certificate96.9of 100Extensively documentedVisit Origin Labs - 2
Next Gen Peptides$2.00/mg listed · 12 Tirzepatide certificates93.6of 100Extensively documentedVisit Next Gen Peptides - 3
Ascend Science$4.55/mg listed · 6 Tirzepatide certificates92.9of 100Extensively documentedVisit Ascend Science
Ranked on this compound's price per mg against the market median, with testing and documentation counted as they are overall. A regulatory action against a vendor is recorded on that vendor's profile and counts against its score.